(ATDN) New HIV and KS drug being studied

(ATDN) New HIV and KS drug being studied

Treatment Review No. 14; November 1994

A new drug that may help treat KS is being studied in people both with and without KS in New York City. The study is open to people with less than 300 T4 cells. The drug is a receptor for IL-1. IL-1 is cytokine produced in response to infection or injury which causes inflammation.

Cytokines are messengers, or communicators, produced by immune system cells. IL-1 has been associated with the growth of KS cells. This drug may be able to attract IL-1 and prevent it from causing disease progression. The name of the drug is rhu-IL1R, which stands for soluble recombinant interleukin-1 receptor.

To participate in this study, you must have been taking an approved antiretroviral, such as AZT or ddI, at a stable dose for at least 2 months. You cannot have active disease. For information about this study, or any other study or drug for KS or AIDS call The Network at (800) 858-2111.

941101
ATR01403

Always watch for outdated information. This article first appeard in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1994 - AIDS Treatment Data Network. If you want to copy, reproduce or excerpt this information, please give us a call at (800) 734-7104. This helps up to keep track of where and how this information is being used. You can also Email us at network@atdn.org http://206.179.124.69/network/index.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1994. AEGIS.